Hoechst Pakistan Limited (PSX:HPL)

Market Cap	31.27B
Revenue (ttm)	26.75B
Net Income (ttm)	1.86B
Shares Out	9.64M
EPS (ttm)	192.56
PE Ratio	16.84
Forward PE	n/a
Dividend	135.00 (4.16%)
Ex-Dividend Date	Mar 26, 2025

Volume	75
Average Volume	306
Open	3,101.00
Previous Close	3,193.87
Day's Range	3,101.00 - 3,299.99
52-Week Range	1,210.01 - 3,480.00
Beta	0.23
RSI	59.40
Earnings Date	Mar 26, 2025

About Hoechst Pakistan

Hoechst Pakistan Limited engages in the manufacture, trading, and sale of pharmaceutical and related products in Pakistan, Afghanistan, and internationally. The company provides its antibiotic, cardiology, diabetes, pain and allergy, and other products under Flagyl, Clexane, NO-SPA, Lantus, Amaryl, Claforan, Haemaccel, Enterogermina, and Plavix brands. It also offers various shampoos under the Selsun Blue brand name. The company was formerly known as Sanofi-Aventis Pakistan Limited and changed its name to Hoechst Pakistan Limited in September 2...

• Industry: Pharmaceutical Preparations
• Founded: 1967
• Employees: 837
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: HPL

Financial Performance

In 2024, Hoechst Pakistan's revenue was 26.75 billion, an increase of 25.17% compared to the previous year's 21.37 billion. Earnings were 1.86 billion, an increase of 414.72%.